Aldeyra Therapeutics, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Aldeyra Therapeutics is a clinical-stage biotechnology company developing therapies for immune-mediated and metabolic diseases, including reproxalap, ADX-629, ADX-246, ADX-248, and ADX-2191. The filing covers the three months ended March 31, 2024; financial statements are unaudited.
The company has no products approved for sale and generated no product revenue during the period. Its principal programs remain dependent on clinical development, regulatory approval, and potential commercialization partnerships.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | None reported | None reported | No product revenue |
| Research and development expense | $6.2 million | $11.2 million | Down $5.0 million |
| General and administrative expense | $3.2 million | $5.6 million | Down $2.4 million |
| Loss from operations | $9.4 million | $16.8 million | Loss narrowed $7.4 million |
| Net loss | $8.1 million | $15.6 million | Loss narrowed $7.5 million |
| Net loss per share | $0.14 | $0.27 | Improved |
| Net cash used in operating activities | $10.0 million | $9.4 million | Use increased $0.5 million |
Net other income was $1.3 million, consisting primarily of $1.8 million of interest income partially offset by $0.5 million of interest expense. Comprehensive loss was $8.1 million, including a $3,000 unrealized loss on marketable securities.
At March 31, 2024, cash and cash equivalents were $102.5 million, marketable securities were $30.5 million, and total cash, cash equivalents, and marketable securities were $133.0 million. Total assets were $141.3 million and stockholders’ equity was $113.4 million. Accumulated deficit was $402.3 million.
Debt consisted principally of a $15.0 million Hercules term loan, classified as current, plus a $292,500 supplemental end-of-term charge, net of unamortized debt issuance costs. The effective interest rate was 13.2%. The company was in material compliance with its debt covenants as of March 31, 2024.
Material changes versus the prior comparable period
- Research and development expense declined 45%, primarily due to lower external clinical development, personnel, and consulting costs.
- General and administrative expense declined 42%, primarily due to lower personnel, consulting, and legal costs.
- Net loss declined approximately 48%, although operating cash use increased modestly because of changes in accrued expenses and prepaid research and development costs.
- Cash, cash equivalents, and marketable securities declined from $142.8 million in cash and cash equivalents at December 31, 2023 to $133.0 million at March 31, 2024. The decrease reflected $10.0 million of operating cash use and a $30.4 million purchase of marketable securities; the latter represents a reallocation of cash rather than an equivalent additional operating loss.
- Marketable securities increased to $30.5 million from none at year-end 2023, while cash equivalents included a $50.0 million reverse repurchase agreement.
- Stock-based compensation expense decreased to $1.5 million from $4.2 million.
- Shares outstanding increased to 59.4 million at March 31, 2024 from 59.2 million at December 31, 2023, primarily reflecting employee stock purchase plan activity and vested restricted stock awards.
Guidance, outlook, risks, contingencies, and unusual items
Management stated that, based on its current operating plan, cash, cash equivalents, and marketable securities should fund projected operating expenses and debt obligations beyond the end of 2026. This assessment depends on assumptions regarding development costs, regulatory timing, clinical results, commercialization requirements, and financing or collaboration outcomes. Management also stated that substantial additional capital will be required in the future.
Reproxalap received a Complete Response Letter from the FDA in November 2023. The FDA stated that the NDA did not demonstrate efficacy for ocular symptoms associated with dry eye and indicated that at least one additional adequate and well-controlled study was needed. Aldeyra is discussing a proposed dry-eye chamber crossover trial with the FDA and expects to initiate the trial, but there is no assurance that the trial design or results will support an NDA resubmission or approval.
AbbVie paid $6.0 million for an exclusive option related to a potential reproxalap collaboration. The amount remains deferred collaboration revenue and will be recognized if the option is exercised or expires. As of April 30, 2024, AbbVie had not exercised the option. If exercised and the collaboration agreement is executed, AbbVie would pay a $100 million upfront amount less the $6.0 million already paid, with potential regulatory and commercial milestones of approximately $300 million, a 60%/40% U.S. profit-and-loss split in AbbVie’s favor, and tiered royalties outside the United States.
On April 29, 2024, after the reporting date, the Hercules facility was amended to extend the interest-only period from May 1, 2024 to October 1, 2024. The loan maturity date remains October 1, 2024, and future payments, including the supplemental end-of-term charge, totaled approximately $15.3 million as of March 31, 2024.
The company expects continued operating losses. It does not expect reproxalap or another product candidate to be commercially available before at least the first half of 2025, if at all. In January 2024, Aldeyra deprioritized ADX-629 programs in chronic cough and idiopathic nephrotic syndrome and deprioritized ADX-2191 programs for proliferative vitreoretinopathy and primary vitreoretinal lymphoma following regulatory and feasibility challenges.
A purported stockholder securities class action remains pending in federal court, alleging misleading statements concerning ADX-2191 and reproxalap. A separate derivative action was filed in March 2024. The company disputes the claims and stated that it cannot reasonably predict outcomes or estimate potential losses. A previously filed derivative action was voluntarily dismissed without prejudice.
Other material risks include FDA approval uncertainty, clinical-trial execution and enrollment, reliance on third-party manufacturers and contract research organizations, need for additional financing, potential dilution, debt covenants and secured collateral, intellectual-property protection, litigation, cybersecurity, reimbursement and pricing pressure, and competition.
Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2024, and reported no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether the FDA provides favorable feedback on the proposed reproxalap dry-eye trial and whether Aldeyra initiates and completes it on schedule.
- Whether AbbVie exercises its option before the applicable deadline and whether a collaboration agreement is executed.
- The company’s cash burn, investment balances, and ability to fund operations beyond 2026 under changing clinical and commercialization assumptions.
- The October 1, 2024 Hercules maturity date, the effect of the April 2024 amendment, and the company’s ability to repay or refinance approximately $15.3 million.
- Progress, costs, and regulatory status of ADX-629, ADX-246, ADX-248, and ADX-2191 following the stated program deprioritizations.
- Potential financial and reputational effects of the pending securities class action and derivative litigation.
- Future equity or debt financings, potential dilution, and the availability of additional capital on acceptable terms.